Search

Displaying results 5131 - 5140 of 10000 in total
  1. Drug

    MD-0727

    go.drugbank.com/drugs/DB05948
    Investigational

    MD-0727 is a novel, potent cholesterol absorption inhibitor (CAI) under investigation for the treatment of hypercholesterolemia (high cholesterol.

  2. Drug

    Otenabant

    go.drugbank.com/drugs/DB11745
    Investigational

    Otenabant has been investigated for the treatment of Obesity.

  3. Drug

    10-hydroxycamptothecin

    go.drugbank.com/drugs/DB12385
    Experimental

    10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).

  4. Drug

    X-376

    go.drugbank.com/drugs/DB13104
    Investigational

    X-376 is an inhibitor of the anaplastic lymphoma kinase (ALK) which can penetrate the blood brain barrier.[A265085]

  5. Drug

    SMART101

    go.drugbank.com/drugs/DB18370
    Investigational

    SMART101 is an investigational cell therapy comprising human allogeneic CD34-CD7+ T cell progenitors that were cultured ex vivo.

  6. Drug

    ALLO-605

    go.drugbank.com/drugs/DB18641
    Investigational

    ALLO-605 is an allogeneic turbo chimeric antigen receptor (Turbocar) T Cell therapy targeting B Cell maturation antigen (BCMA).

  7. Drug

    RC88

    go.drugbank.com/drugs/DB18697
    Experimental

    RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).

  8. Drug

    ORC-13661

    go.drugbank.com/drugs/DB18903
    Investigational

    ORC-13661 is under investigation in clinical trial NCT05730283 (Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin).

  9. Drug

    Povetacicept

    go.drugbank.com/drugs/DB18996
    Investigational

    Povetacicept is under investigation in clinical trial NCT05757570 (An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias).

  10. Drug

    LP-2307

    go.drugbank.com/drugs/DB17470
    Experimental

    LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.